Could a daily pill replace insulin for kidney transplant patients?

NCT ID NCT05702931

Recruiting now Disease control Sponsor: Rigshospitalet, Denmark Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether oral semaglutide (Rybelsus) can safely control high blood sugar in people who recently had a kidney transplant. About 104 participants will receive either the drug or a placebo for 14 weeks, alongside standard care. The goal is to see if it works as well as insulin without harming the new kidney or causing dangerous low blood sugar.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Semaglutide (Rybelsus) - a tablet that lowers blood sugar and helps with weight loss
What this could lead to: If it works, this could offer a safer, more convenient alternative to insulin for managing high blood sugar after kidney transplant, potentially reducing weight gain and hypoglycemia risk.
What could go wrong: This is a small, early-phase trial (104 people) testing a drug not yet proven safe in transplant recipients. There are concerns about kidney graft function and gastrointestinal side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus hyperglycemia type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES HYPERGLYCEMIA RENAL TRANSPLANT COMPLICATION PRIMARY NON-FUNCTION

Contacts and locations

Locations

Department og Nephrology and Endocrinology, Rigshospitalet
RECRUITING

Copenhagen, 2100, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.